News
The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback